FluoroPharma Medical Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of FluoroPharma Medical Inc in the market are Cardinal Health, Bracco Imaging, and GE Healthcare.

FluoroPharma Medical Inc is a specialized molecular imaging company that develops pharmaceuticals to enhance patient care. Founded in 2003, the company focuses on the research and development of innovative diagnostic imaging agents with specific applications in cardiology, oncology, and neurology. FluoroPharma's cutting-edge technologies enable medical professionals to accurately identify and assess various medical conditions and diseases. With a strong commitment to advancing personalized medicine, FluoroPharma Medical Inc utilizes positron emission tomography (PET) imaging to provide precise diagnostic information, aiding in early detection and effective treatment planning. This commitment to groundbreaking molecular imaging solutions makes FluoroPharma Medical Inc a trusted leader in the field.

FluoroPharma Medical Inc has achieved several significant milestones. The company successfully completed a Phase II clinical trial for CardioPET, an imaging agent used to detect cardiac ischemia. Additionally, FluoroPharma received clearance from the U.S. FDA to begin Phase II trials for BFPET, a diagnostic imaging agent for Alzheimer's disease. Furthermore, the company entered into a strategic collaboration with Advanced Accelerator Applications to develop and commercialize cardiovascular imaging agents. These achievements demonstrate FluoroPharma's commitment to advancing innovative imaging technologies for improved patient care.

FluoroPharma Medical Inc is primarily present in the United States.

FluoroPharma Medical Inc represents values of innovation, dedication, and commitment to improving healthcare through cutting-edge molecular imaging agents. With a strong corporate philosophy centered around research and development of novel imaging agents, FluoroPharma Medical Inc aims to provide physicians and patients with advanced diagnostic tools for better disease detection and treatment. By continuously seeking innovative solutions and leveraging its expertise in molecular imaging, FluoroPharma Medical Inc strives to enhance patient care and contribute to the advancement of personalized medicine.

Converted at the current exchange rate, the FluoroPharma Medical share trades at 0,00 EUR (0,00 USD).

FluoroPharma Medical Inc is a company specialized in developing innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. Its business model aims to develop and distribute these innovative drugs and technologies to medical institutions, research facilities, and pharmaceutical companies worldwide. One of FluoroPharma's core areas is the conception and development of molecular imaging solutions. These solutions allow for the early detection of diseases before they manifest and lead to serious health complications. The company manufactures its imaging solutions in collaboration with leading scientists, clinical researchers, and experts in biomedical imaging. Another core area of FluoroPharma is clinical research and development. The company continuously conducts clinical studies to evaluate the efficacy and safety of its products. It employs highly qualified medical professionals involved in the development and execution of clinical studies. This ensures that FluoroPharma's products meet the highest standards and deliver the best possible results to patients. FluoroPharma has a portfolio of innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. The company develops and sells both therapeutic and diagnostic imaging solutions. The diagnostic portfolio includes PET imaging solutions such as CardioPET, the earliest PET imaging solution for patients. The company also offers BFPET, an innovative proprietary PET imaging solution for the diagnosis of breast cancer. FluoroPharma also manufactures therapeutic imaging agents used for targeted diagnosis and treatment of diseases. One such imaging agent is AZPET, an innovative PET imaging agent for the diagnosis and treatment of prostate cancer administered in conjunction with targeted therapy. FluoroPharma Medical has achieved broad market presence through partnerships and strategic alliances with research institutions and pharmaceutical companies in the United States and Europe. The company has an experienced and dedicated team of experts in all areas - from research and development to sales strategy. This expertise enables FluoroPharma to be successful in the market and maintain a leading position in the field of molecular imaging solutions. Overall, we can say that FluoroPharma Medical Inc. is an innovative company that offers a wide range of molecular imaging solutions and has a deep understanding of the needs of patients, physicians, and pharmaceuticals. Through collaboration with leading scientists and experts, the company strives to develop sophisticated products and services to improve patients' lives and promote health.

Liikevaihtoa ei voida laskea FluoroPharma Medical:lle tällä hetkellä.

Voittoa ei voida laskea FluoroPharma Medical:lle tällä hetkellä.

P/E-suhdetta ei voida laskea FluoroPharma Medical:lle tällä hetkellä.

P/S-suhdetta ei voida laskea FluoroPharma Medical:lle tällä hetkellä.

FluoroPharma Medical:n Eulpool-laatuscore on 2/10.

FluoroPharma Medical:n ISIN on US3438701019. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

FluoroPharma Medical:n ticker on FPMI. Tämä pörssinoteeraus käytetään FluoroPharma Medical-osakkeiden kauppaan pörssissä.

FluoroPharma Medical maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

FluoroPharma Medical kuuluu sektoriin 'Terveydenhuolto'.

FluoroPharma Medical:n osingot jaetaan valuutassa USD.